CSPG4: a prototype oncoantigen for translational immunotherapy studies

Abstract Thanks to striking progress in both the understanding of anti-tumor immune response and the characterization of several tumor associated antigens (TAA), a more rational design and more sophisticated strategies for anti-tumor vaccination have been possible. However, the effectiveness of canc...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Valeria Rolih, Giuseppina Barutello, Selina Iussich, Raffaella De Maria, Elena Quaglino, Paolo Buracco, Federica Cavallo, Federica Riccardo
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMC 2017-07-01
Serier:	Journal of Translational Medicine
Fag:	Chondroitin sulfate proteoglycan-4 (CSPG4) Cancer immunotherapy Comparative oncology DNA vaccination
Online adgang:	http://link.springer.com/article/10.1186/s12967-017-1250-4
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!